Cantargia AB (CANTA) - Total Liabilities

Latest as of September 2025: Skr61.31 Million SEK ≈ $6.60 Million USD

Based on the latest financial reports, Cantargia AB (CANTA) has total liabilities worth Skr61.31 Million SEK (≈ $6.60 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore CANTA net asset momentum to track the company's year-over-year net asset growth rate.

Cantargia AB - Total Liabilities Trend (2011–2024)

This chart illustrates how Cantargia AB's total liabilities have evolved over time, based on quarterly financial data. See CANTA cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Cantargia AB Competitors by Total Liabilities

The table below lists competitors of Cantargia AB ranked by their total liabilities.

Company Country Total Liabilities
Nam Kwang Cons
KO:001260
Korea ₩276.26 Billion
Strongpoint ASA
OL:STRO
Norway Nkr529.41 Million
PBG S.A
SA:PTBL3
Brazil R$3.37 Billion
Done.ai Group AB
ST:TINGS-B
USA Skr2.19 Billion
OptimumBank Holdings, Inc.
NASDAQ:OPHC
USA $966.15 Million
Arena Bilgisayar Sanayi ve Ticaret AS
IS:ARENA
Turkey TL11.85 Billion
Intrum Justitia AB
ST:INTRUM
Sweden Skr55.88 Billion
KESM Industries Bhd
KLSE:9334
Malaysia RM68.87 Million

Liability Composition Analysis (2011–2024)

This chart breaks down Cantargia AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CANTA market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 5.82 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.21 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.17 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cantargia AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cantargia AB (2011–2024)

The table below shows the annual total liabilities of Cantargia AB from 2011 to 2024.

Year Total Liabilities Change
2024-12-31 Skr54.12 Million
≈ $5.82 Million
-1.54%
2023-12-31 Skr54.97 Million
≈ $5.92 Million
-35.42%
2022-12-31 Skr85.11 Million
≈ $9.16 Million
+26.10%
2021-12-31 Skr67.50 Million
≈ $7.26 Million
+101.02%
2020-12-31 Skr33.58 Million
≈ $3.61 Million
+41.18%
2019-12-31 Skr23.78 Million
≈ $2.56 Million
+45.04%
2018-12-31 Skr16.40 Million
≈ $1.76 Million
-42.12%
2017-12-31 Skr28.33 Million
≈ $3.05 Million
+172.85%
2016-12-31 Skr10.38 Million
≈ $1.12 Million
+212.02%
2015-12-31 Skr3.33 Million
≈ $358.15K
-79.24%
2014-12-31 Skr16.03 Million
≈ $1.73 Million
+1768.34%
2013-12-31 Skr858.07K
≈ $92.34K
+23.05%
2012-12-31 Skr697.32K
≈ $75.04K
-19.04%
2011-12-31 Skr861.27K
≈ $92.69K
--

About Cantargia AB

ST:CANTA Sweden Biotechnology
Market Cap
$47.30 Million
Skr439.55 Million SEK
Market Cap Rank
#22057 Global
#415 in Sweden
Share Price
Skr1.77
Change (1 day)
-2.96%
52-Week Range
Skr1.77 - Skr6.20
All Time High
Skr58.00
About

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which… Read more